NCT03576443View on ClinicalTrials.gov

Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 7, 2017

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Idelalisib

Idelalisib 150 mg x 2 p o

Trial Locations (6)

8000

Aarhus University Hospital, Aarhus C

Unknown

Odense University Hospital, Odense

30 233

Halmstad County Hospital, Halmstad

581 85

Linkoping University Hospital, Linköping

221 85

Skane University Hospital, Lund

141 86

Karolinska University Hospital, Stockholm

All Listed Sponsors
lead

Nordic Lymphoma Group

NETWORK

NCT03576443 - Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter